XML 40 R24.htm IDEA: XBRL DOCUMENT
v3.24.2.u1

Significant Accounting Policies (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2024
Accounting Policies [Abstract] |
Schedule of reconciliation of cash and cash equivalents | The following is a reconciliation of cash and cash equivalents on the unaudited condensed consolidated balance sheets to total cash, cash equivalents and restricted cash on the unaudited condensed consolidated statements of cash flows:
In millions | June 30, 2024 |  | December 31, 2023 |  |
Cash and cash equivalents | $ | 12,507 |  |  | $ | 8,196 |  |  |
Restricted cash (included in other current assets) | 54 |  |  | 90 |  |  |
Restricted cash (included in other assets) | 259 |  |  | 239 |  |  |
Total cash, cash equivalents and restricted cash in the statements of cash flows | $ | 12,820 |  |  | $ | 8,525 |  |  |
Schedule of accounts receivable, net | Accounts receivable, net at June 30, 2024 and December 31, 2023 was composed of the following:
In millions | June 30, 2024 |  | December 31, 2023
Trade receivables | $ | 9,793 |  |  | $ | 11,908 |
Vendor and manufacturer receivables | 13,528 |  |  | 15,711 |
Premium receivables | 4,430 |  |  | 3,714 |
Other receivables | 4,634 |  |  | 3,894 |
Total accounts receivable, net | $ | 32,385 |  |  | $ | 35,227 |
Roll forward of deferred acquisition costs | The following is a roll forward of deferred acquisition costs for the six months ended June 30, 2024 and 2023:
|  |  | Six Months Ended June 30,
In millions |  |  |  |  | 2024 |  | 2023
Deferred acquisition costs, beginning of the period |  |  |  |  | $ | 1,502 |  | $ | 1,219
Capitalizations |  |  |  |  | 271 |  | 274
Amortization expense |  |  |  |  | (146) |  | (128)
Deferred acquisition costs, end of the period |  |  |  |  | $ | 1,627 |  | $ | 1,365
Schedule of disaggregation of revenue | The following tables disaggregate the Company’s revenue by major source in each segment for the three and six months ended June 30, 2024 and 2023:
In millions | Health Care Benefits |  | Health Services |  | Pharmacy & Consumer Wellness |  | Corporate/ Other |  | Intersegment Eliminations |  | Consolidated Totals
Three Months Ended June 30, 2024 |  |  |  |  |  |  |  |
Major goods/services lines: |  |  |  |  |  |  |  |  |  |  |
Pharmacy | $ | — |  |  | $ | 39,499 |  |  | $ | 24,013 |  |  | $ | — |  |  | $ | (12,532) |  |  | $ | 50,980 |
Front Store | — |  |  | — |  |  | 5,281 |  |  | — |  |  | — |  |  | 5,281 |
Premiums | 30,654 |  |  | — |  |  | — |  |  | 13 |  |  | — |  |  | 30,667 |
Net investment income (loss) | 300 |  |  | (2) |  |  | — |  |  | 96 |  |  | — |  |  | 394 |
Other | 1,521 |  |  | 2,674 |  |  | 544 |  |  | 2 |  |  | (829) |  |  | 3,912 |
Total | $ | 32,475 |  |  | $ | 42,171 |  |  | $ | 29,838 |  |  | $ | 111 |  |  | $ | (13,361) |  |  | $ | 91,234 |
Health Services distribution channel: |  |  |  |  |  |  |  |
Pharmacy network (1) |  |  | $ | 21,848 |  |  |  |  |  |  |  |  |
Mail & specialty (2) |  |  | 17,651 |  |  |  |  |  |  |  |  |
Other |  |  | 2,674 |  |  |  |  |  |  |  |  |
Net investment income (loss) |  |  | (2) |  |  |  |  |  |  |  |  |
Total |  |  | $ | 42,171 |  |  |  |  |  |  |  |  |
Three Months Ended June 30, 2023 |  |  |  |  |  |  |  |
Major goods/services lines: |  |  |  |  |  |  |  |  |  |  |
Pharmacy | $ | — |  |  | $ | 44,706 |  |  | $ | 22,614 |  |  | $ | — |  |  | $ | (12,258) |  |  | $ | 55,062 |
Front Store | — |  |  | — |  |  | 5,629 |  |  | — |  |  | — |  |  | 5,629 |
Premiums | 25,095 |  |  | — |  |  | — |  |  | 13 |  |  | — |  |  | 25,108 |
Net investment income | 205 |  |  | — |  |  | 1 |  |  | 68 |  |  | — |  |  | 274 |
Other | 1,447 |  |  | 1,509 |  |  | 540 |  |  | 2 |  |  | (650) |  |  | 2,848 |
Total | $ | 26,747 |  |  | $ | 46,215 |  |  | $ | 28,784 |  |  | $ | 83 |  |  | $ | (12,908) |  |  | $ | 88,921 |
Health Services distribution channel: |  |  |  |  |  |  |  |
Pharmacy network (1) |  |  | $ | 27,477 |  |  |  |  |  |  |  |  |
Mail & specialty (2) |  |  | 17,229 |  |  |  |  |  |  |  |  |
Other |  |  | 1,509 |  |  |  |  |  |  |  |  |
Total |  |  | $ | 46,215 |  |  |  |  |  |  |  |  |
In millions | Health Care Benefits |  | Health Services |  | Pharmacy & Consumer Wellness |  | Corporate/ Other |  | Intersegment Eliminations |  | Consolidated Totals
Six Months Ended June 30, 2024 |  |  |  |  |  |  |  |
Major goods/services lines: |  |  |  |  |  |  |  |  |  |  |
Pharmacy | $ | — |  |  | $ | 77,225 |  |  | $ | 46,797 |  |  | $ | — |  |  | $ | (24,645) |  |  | $ | 99,377 |
Front Store | — |  |  | — |  |  | 10,651 |  |  | — |  |  | — |  |  | 10,651 |
Premiums | 61,033 |  |  | — |  |  | — |  |  | 25 |  |  | — |  |  | 61,058 |
Net investment income (loss) | 653 |  |  | (2) |  |  | — |  |  | 197 |  |  | — |  |  | 848 |
Other | 3,025 |  |  | 5,233 |  |  | 1,115 |  |  | 4 |  |  | (1,640) |  |  | 7,737 |
Total | $ | 64,711 |  |  | $ | 82,456 |  |  | $ | 58,563 |  |  | $ | 226 |  |  | $ | (26,285) |  |  | $ | 179,671 |
Health Services distribution channel: |  |  |  |  |  |  |  |
Pharmacy network (1) |  |  | $ | 42,312 |  |  |  |  |  |  |  |  |
Mail & specialty (2) |  |  | 34,913 |  |  |  |  |  |  |  |  |
Other |  |  | 5,233 |  |  |  |  |  |  |  |  |
Net investment income (loss) |  |  | $ | (2) |  |  |  |  |  |  |  |  |
Total |  |  | $ | 82,456 |  |  |  |  |  |  |  |  |
Six Months Ended June 30, 2023 |  |  |  |  |  |  |  |
Major goods/services lines: |  |  |  |  |  |  |  |  |  |  |
Pharmacy | $ | — |  |  | $ | 88,443 |  |  | $ | 44,394 |  |  | $ | — |  |  | $ | (24,990) |  |  | $ | 107,847 |
Front Store | — |  |  | — |  |  | 11,226 |  |  | — |  |  | — |  |  | 11,226 |
Premiums | 49,434 |  |  | — |  |  | — |  |  | 26 |  |  | — |  |  | 49,460 |
Net investment income (loss) | 369 |  |  | — |  |  | (2) |  |  | 241 |  |  | — |  |  | 608 |
Other | 2,821 |  |  | 2,363 |  |  | 1,088 |  |  | 4 |  |  | (1,218) |  |  | 5,058 |
Total | $ | 52,624 |  |  | $ | 90,806 |  |  | $ | 56,706 |  |  | $ | 271 |  |  | $ | (26,208) |  |  | $ | 174,199 |
Health Services distribution channel: |  |  |  |  |  |  |  |
Pharmacy network (1) |  |  | $ | 55,069 |  |  |  |  |  |  |  |  |
Mail & specialty (2) |  |  | 33,374 |  |  |  |  |  |  |  |  |
Other |  |  | 2,363 |  |  |  |  |  |  |  |  |
Total |  |  | $ | 90,806 |  |  |  |  |  |  |  |  |
_____________________________________________ (1)Health Services pharmacy network is defined as claims filled at retail and specialty retail pharmacies, including the Company’s retail pharmacies and LTC pharmacies, as well as activity associated with Maintenance Choice®, which permits eligible client plan members to fill their maintenance prescriptions through mail order delivery or at a CVS pharmacy retail store for the same price as mail order. (2)Health Services mail & specialty is defined as specialty mail claims inclusive of Specialty Connect® claims picked up at a retail pharmacy, as well as mail order and specialty claims fulfilled by the Pharmacy & Consumer Wellness segment.
Schedule of receivables and contract liabilities from contracts with customers | The following table provides information about receivables and contract liabilities from contracts with customers:
In millions | June 30, 2024 |  | December 31, 2023
Trade receivables (included in accounts receivable, net) | $ | 9,793 |  |  | $ | 11,908 |
Contract liabilities (included in accrued expenses) | 128 |  |  | 149 |

X
- References No definition available. + Details
Name: | us-gaap_AccountingPoliciesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the movement in deferred policy acquisition costs. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479432/944-30-50-2B Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479432/944-30-50-2B Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 944 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479401/944-30-55-2 + Details
Name: | us-gaap_DeferredPolicyAcquisitionCostsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of supplemental cash flow information for the periods presented. + References No definition available. + Details
Name: | us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration